• Product nameAnti-CTLA4 antibody
    See all CTLA4 primary antibodies
  • Description
    Rabbit polyclonal to CTLA4
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    KLH conjugated synthetic peptide corresponding to a region within N terminal amino acids 57-86 of Human CTLA4 (NP_005205.2, NP_001032720.1).

  • Positive control
    • WiDr cell line lysate



Our Abpromise guarantee covers the use of ab107198 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/500. Predicted molecular weight: 25 kDa.


  • FunctionInhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
  • Tissue specificityWidely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation.
  • Involvement in diseaseGenetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE) [MIM:152700]. SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
    Note=Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism.
    Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12) [MIM:601388]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
    Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3) [MIM:609755]. It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive.
  • Sequence similaritiesContains 1 Ig-like V-type (immunoglobulin-like) domain.
  • Post-translational
    N-glycosylation is important for dimerization.
    Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface.
  • Cellular localizationCell membrane. Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation and.
  • Information by UniProt
  • Database links
  • Alternative names
    • ALPS5 antibody
    • CD 152 antibody
    • CD antibody
    • CD152 antibody
    • CD152 antigen antibody
    • CD152 isoform antibody
    • Celiac disease 3 antibody
    • CELIAC3 antibody
    • CTLA 4 antibody
    • CTLA-4 antibody
    • CTLA4 antibody
    • CTLA4_HUMAN antibody
    • Cytotoxic T cell associated 4 antibody
    • Cytotoxic T lymphocyte antigen 4 antibody
    • Cytotoxic T lymphocyte associated 4 antibody
    • Cytotoxic T lymphocyte associated 4, soluble isoform, included antibody
    • Cytotoxic T lymphocyte associated antigen 4 antibody
    • Cytotoxic T lymphocyte associated antigen 4 short spliced form antibody
    • Cytotoxic T lymphocyte associated protein 4 antibody
    • Cytotoxic T lymphocyte associated serine esterase 4 antibody
    • Cytotoxic T lymphocyte protein 4 antibody
    • Cytotoxic T-lymphocyte protein 4 antibody
    • Cytotoxic T-lymphocyte-associated antigen 4 antibody
    • GRD4 antibody
    • GSE antibody
    • ICOS antibody
    • IDDM12 antibody
    • insulin-dependent diabetes mellitus 12 antibody
    • Ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4 antibody
    • OTTHUMP00000216623 antibody
    see all

Anti-CTLA4 antibody images

  • Anti-CTLA4 antibody (ab107198) at 1/100 dilution + WiDr cell line lysate at 35 µg

    Predicted band size : 25 kDa
  • Anti-CTLA4 antibody (ab107198) at 1 µg/ml + Human CTLA4 full length protein (ab69787) at 0.1 µg/ml

    Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Exposure time : 20 seconds

References for Anti-CTLA4 antibody (ab107198)

ab107198 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab107198.
Please use the links above to contact us or submit feedback about this product.